Literature DB >> 20851924

Rheumatoid arthritis-interstitial lung disease-associated mortality.

Amy L Olson1, Jeffrey J Swigris, David B Sprunger, Aryeh Fischer, Evans R Fernandez-Perez, Josh Solomon, James Murphy, Marc Cohen, Ganesh Raghu, Kevin K Brown.   

Abstract

RATIONALE: Mortality rates from rheumatoid arthritis-associated interstitial lung disease (RA-ILD) are largely unknown.
OBJECTIVES: We sought to determine mortality rates from rheumatoid arthritis-associated interstitial lung disease in the United States from 1988 through 2004.
METHODS: Using data from the National Center for Health Statistics, we calculated age-adjusted mortality rates from the deaths of persons with rheumatoid arthritis-associated interstitial lung disease, determined the prevalence of interstitial lung disease in all decedents with rheumatoid arthritis, and compared the age and underlying cause of death in these two cohorts of decedents.
MEASUREMENTS AND MAIN RESULTS: From 1988 to 2004, there were 39,138,394 deaths in U.S. residents and 162,032 rheumatoid arthritis-associated deaths. Of these deaths, 10,725 (6.6%) met criteria for rheumatoid arthritis-associated interstitial lung. Mortality rates from rheumatoid arthritis fell over the course of this study in both women and men. However, mortality rates from rheumatoid arthritis-associated interstitial lung disease increased 28.3% in women (to 3.1 per million persons in 2004) and declined 12.5% in men (to 1.5 per million persons in 2004). Because the rate of decline in rheumatoid arthritis outpaced rheumatoid arthritis-associated interstitial lung disease in men, the prevalence of rheumatoid arthritis-associated interstitial lung disease increased in both sexes over time.
CONCLUSIONS: Clinically significant RA-ILD occurs in nearly 10% of the RA population, and is associated with shortened survival and more severe underlying disease. Whereas overall mortality rates for RA have fallen, those associated with RA-ILD have increased significantly in older age groups.

Entities:  

Mesh:

Year:  2010        PMID: 20851924      PMCID: PMC5450769          DOI: 10.1164/rccm.201004-0622OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  22 in total

1.  Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001).

Authors:  J Ledingham; C Deighton
Journal:  Rheumatology (Oxford)       Date:  2005-01-05       Impact factor: 7.580

Review 2.  Usual interstitial pneumonia.

Authors:  Joseph P Lynch; Rajan Saggar; S Sam Weigt; David A Zisman; Eric S White
Journal:  Semin Respir Crit Care Med       Date:  2006-12       Impact factor: 3.119

3.  What kills patients with rheumatoid arthritis?

Authors:  C Kelly; J Hamilton
Journal:  Rheumatology (Oxford)       Date:  2006-09-26       Impact factor: 7.580

4.  Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study.

Authors:  Tim Bongartz; Carlotta Nannini; Yimy F Medina-Velasquez; Sara J Achenbach; Cynthia S Crowson; Jay H Ryu; Robert Vassallo; Sherine E Gabriel; Eric L Matteson
Journal:  Arthritis Rheum       Date:  2010-06

5.  Pulmonary involvement in rheumatoid arthritis.

Authors:  Ayhan Bilgici; H Ulusoy; O Kuru; C Celenk; M Unsal; M Danaci
Journal:  Rheumatol Int       Date:  2004-07-28       Impact factor: 2.631

6.  3. Sampling variance of standardized mortality rates.

Authors:  N Keyfitz
Journal:  Hum Biol       Date:  1966-09       Impact factor: 0.553

7.  Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden, 1964-95.

Authors:  Lena Björnådal; Eva Baecklund; Li Yin; Fredrik Granath; Lars Klareskog; Anders Ekbom
Journal:  J Rheumatol       Date:  2002-05       Impact factor: 4.666

8.  Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003.

Authors:  Amy L Olson; Jeffrey J Swigris; Dennis C Lezotte; Jill M Norris; Carla G Wilson; Kevin K Brown
Journal:  Am J Respir Crit Care Med       Date:  2007-05-03       Impact factor: 21.405

Review 9.  Management of extra-articular disease manifestations in rheumatoid arthritis.

Authors:  Carl Turesson; Eric L Matteson
Journal:  Curr Opin Rheumatol       Date:  2004-05       Impact factor: 5.006

10.  Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Sandra Muñoz; Natalia Soria; Diana Galiana; Laura Bertolaccini; Maria-Jose Cuadrado; Munther A Khamashta
Journal:  Medicine (Baltimore)       Date:  2007-07       Impact factor: 1.889

View more
  121 in total

Review 1.  Update in diffuse parenchymal lung disease 2011.

Authors:  Tracy R Luckhardt; Joachim Müller-Quernheim; Victor J Thannickal
Journal:  Am J Respir Crit Care Med       Date:  2012-07-01       Impact factor: 21.405

2.  Selective Sexual Dimorphisms in Musculoskeletal and Cardiopulmonary Pathologic Manifestations and Mortality Incidence in the Tumor Necrosis Factor-Transgenic Mouse Model of Rheumatoid Arthritis.

Authors:  Richard D Bell; Emily K Wu; Christopher A Rudmann; Megan Forney; Claire R W Kaiser; Ronald W Wood; Joe V Chakkalakal; Nicole D Paris; Alanna Klose; Guang-Qian Xiao; Javier Rangel-Moreno; Maria L Garcia-Hernandez; Christopher T Ritchlin; Edward M Schwarz; Homaira Rahimi
Journal:  Arthritis Rheumatol       Date:  2019-07-22       Impact factor: 10.995

Review 3.  Lung disease in rheumatoid arthritis.

Authors:  Zulma X Yunt; Joshua J Solomon
Journal:  Rheum Dis Clin North Am       Date:  2015-02-03       Impact factor: 2.670

Review 4.  Management of interstitial lung disease associated with connective tissue disease.

Authors:  Stephen C Mathai; Sonye K Danoff
Journal:  BMJ       Date:  2016-02-24

5.  Retrospective study of the clinical characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease.

Authors:  Yongfeng Zhang; Hongbin Li; Nawei Wu; Xin Dong; Yi Zheng
Journal:  Clin Rheumatol       Date:  2017-02-12       Impact factor: 2.980

Review 6.  Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases.

Authors:  Aryeh Fischer; Jörg Distler
Journal:  Clin Rheumatol       Date:  2019-08-19       Impact factor: 2.980

7.  Performance of Administrative Algorithms to Identify Interstitial Lung Disease in Rheumatoid Arthritis.

Authors:  Bryant R England; Punyasha Roul; Tina D Mahajan; Namrata Singh; Fang Yu; Harlan Sayles; Grant W Cannon; Brian C Sauer; Joshua F Baker; Jeffrey R Curtis; Ted R Mikuls
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-10       Impact factor: 4.794

Review 8.  Comprehensive review of current diagnostic and treatment approaches to interstitial lung disease associated with rheumatoid arthritis.

Authors:  Cemal Bes
Journal:  Eur J Rheumatol       Date:  2018-07-01

9.  Nintedanib reduces pulmonary fibrosis in a model of rheumatoid arthritis-associated interstitial lung disease.

Authors:  Elizabeth F Redente; Martin A Aguilar; Bart P Black; Benjamin L Edelman; Ali N Bahadur; Stephen M Humphries; David A Lynch; Lutz Wollin; David W H Riches
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-03-15       Impact factor: 5.464

10.  Utility of pulmonary ultrasound to identify interstitial lung disease in patients with rheumatoid arthritis.

Authors:  Natalia Mena-Vázquez; Francisco Gabriel Jimenez-Núñez; Francisco Javier Godoy-Navarrete; Sara Manrique-Arija; María Carmen Aguilar-Hurtado; Carmen María Romero-Barco; Inmaculada Ureña-Garnica; F Espildora; María Isabel Padin-Martín; Antonio Fernández-Nebro
Journal:  Clin Rheumatol       Date:  2021-02-21       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.